CHF1.8 million to eliminate critical bottlenecks in traditional drug development

ENANTIOS technology, developed over a five-year research project at ETH Zurich, enables the complete characterization of complex molecules and aspects of the three dimensional structure which are not possible to resolve with other methods. The company's innovative approach based on laser spectroscopy, specifically a technique called Raman Optical Activity (ROA) provides pharmaceutical companies and complex chemical providers with the data and insights needed to accelerate the development of new products. This paves the way to new chemical products and pharmaceutical drugs that are increasingly complex in molecular structure.

Following a convertible loan in 2023, ENANTIOS hs now raised CHF1.8 million. Privilège Ventures led this funding round with additional capital from Zürcher Kantonalbank (ZKB) and several Family Offices and private investors.

“We are thrilled to have the support of such experienced investors who share our vision of the potential of our technology,” said Dr. Carin Lightner, CEO of ENANTIOS. “This funding will allow us to expand our team and accelerate our go-to-market. Our goal is to create a paradigm shift in the development of new pharmaceutics and chemical products.”

Lucian Wagner, General Partner of Privilege Ventures, commented that: “We have been following Enantios for a while and it quickly became clear that they developed truly unique technology with immediate applications within the pharma industry. The team also convinced us in terms of their ambition and drive. We are delighted to add another woman-led company to our portfolio.”

ENANTIOS is bringing to market a new innovative approach to molecular characterization which addresses critical bottlenecks in traditional drug development. The company plans to allocate the seed round funding towards several key initiatives, including:

• Technology Development and Enhancement: Improving the capabilities of ENANTIOS’s proprietary measurement technologies to provide even more precise and comprehensive molecular characterizations.
• Talent Acquisition: Expanding the team with top-tier talent in engineering, science, business, and sales to build up the required infrastructure and pipelines necessary for innovation and execution.
• Strategic Partnerships: Forging collaborations with pharmaceutical companies, academic institutions, and research organizations to leverage collective expertise and resources.

Picture: ENANTIOS team in the lab. From left to right: Madeleine Marchand, Carin Lightner, Roman Wyss, and Monika Dengler
Photo Credit: Jasmin Frei